Aerovate Therapeutics, Inc. (AVTE)
NASDAQ: AVTE · IEX Real-Time Price · USD
1.620
-0.080 (-4.71%)
At close: Jul 2, 2024, 4:00 PM
1.640
+0.020 (1.23%)
After-hours: Jul 2, 2024, 7:55 PM EDT

Aerovate Therapeutics Ratios and Metrics

Millions USD. Fiscal year is Jan - Dec.
Year
Current20232022202120202019
Market Capitalization
47626721288--
Market Cap Growth
64.63%-13.15%150.50%---
Enterprise Value
-52504593121-5-1
PE Ratio
--8.29-14.00-12.53--
PB Ratio
0.515.725.691.67--
P/FCF Ratio
-11.91-11.00-18.34-10.44--
P/OCF Ratio
-11.94-11.03-18.43-10.50--
EV/EBITDA Ratio
-8.84-6.69-11.53-5.270.480.30
EV/EBIT Ratio
-8.83-6.68-11.51-5.270.480.30
EV/FCF Ratio
-10.49-8.86-15.08-4.390.580.36
Debt / Equity Ratio
0.010.010.010.00--0.69
Debt / EBITDA Ratio
-0.01-0.01-0.02-0.03--0.75
Debt / FCF Ratio
-0.01-0.01-0.03-0.02--0.90
Quick Ratio
6.406.9416.6065.642.585.35
Current Ratio
6.657.0416.9068.372.645.35
Interest Coverage
-----127.15-
Return on Equity (ROE)
-70.20%-61.60%-35.60%-29.20%113.20%-
Return on Assets (ROA)
-61.90%-55.10%-34.00%-21.30%-233.60%-
Return on Capital (ROIC)
-96.41%-73.92%-41.65%-13.31%66.61%291.34%
Earnings Yield
-176.02%-12.06%-7.15%-7.98%--
FCF Yield
-148.10%-9.09%-5.45%-9.58%--
Buyback Yield / Dilution
-12.18%-7.60%-99.06%-4975.15%67.70%-
Total Shareholder Return
-12.18%-7.60%-99.06%-4975.15%67.70%-
Source: Financials are provided by Nasdaq Data Link and sourced from the audited annual (10-K) and quarterly (10-Q) reports submitted to the Securities and Exchange Commission (SEC).